» Articles » PMID: 26402693

Preventive Activity Against Influenza (H1N1) Virus by Intranasally Delivered RNA-Hydrolyzing Antibody in Respiratory Epithelial Cells of Mice

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2015 Sep 25
PMID 26402693
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The antiviral effect of a catalytic RNA-hydrolyzing antibody, 3D8 scFv, for intranasal administration against avian influenza virus (H1N1) was described. The recombinant 3D8 scFv protein prevented BALB/c mice against H1N1 influenza virus infection by degradation of the viral RNA genome through its intrinsic RNA-hydrolyzing activity. Intranasal administration of 3D8 scFv (50 μg/day) for five days prior to infection demonstrated an antiviral activity (70% survival) against H1N1 infection. The antiviral ability of 3D8 scFv to penetrate into epithelial cells from bronchial cavity via the respiratory mucosal layer was confirmed by immunohistochemistry, qRT-PCR, and histopathological examination. The antiviral activity of 3D8 scFv against H1N1 virus infection was not due to host immune cytokines or chemokines, but rather to direct antiviral RNA-hydrolyzing activity of 3D8 scFv against the viral RNA genome. Taken together, our results suggest that the RNase activity of 3D8 scFv, coupled with its ability to penetrate epithelial cells through the respiratory mucosal layer, directly prevents H1N1 virus infection in a mouse model system.

Citing Articles

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.

Luong Q, Hoang P, Ho P, Ayun R, Lee T, Lee S Int J Mol Sci. 2025; 26(4).

PMID: 40003946 PMC: 11855616. DOI: 10.3390/ijms26041481.


A synergistic therapy against influenza virus A/H1N1/PR8 by a HA1 specific neutralizing single-domain V and an RNA hydrolyzing scFv.

Hoang P, Luong Q, Ayun R, Lee Y, Oh K, Kim T Front Microbiol. 2024; 15:1355599.

PMID: 38706966 PMC: 11066198. DOI: 10.3389/fmicb.2024.1355599.


An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models.

Luong Q, Hoang P, Lee Y, Ayun R, Na K, Park S Sci Rep. 2024; 14(1):8472.

PMID: 38605110 PMC: 11009316. DOI: 10.1038/s41598-024-52810-0.


A Novel Approach of Antiviral Drugs Targeting Viral Genomes.

Hoang P, Luong Q, Ayun R, Lee Y, Vo T, Kim T Microorganisms. 2022; 10(8).

PMID: 36013970 PMC: 9414836. DOI: 10.3390/microorganisms10081552.


A Therapeutically Active Minibody Exhibits an Antiviral Activity in Oseltamivir-Resistant Influenza-Infected Mice via Direct Hydrolysis of Viral RNAs.

Lee Y, Hoang P, Kim D, Ayun R, Luong Q, Na K Viruses. 2022; 14(5).

PMID: 35632846 PMC: 9146509. DOI: 10.3390/v14051105.


References
1.
Suliman H, Ryan L, Bishop L, Folz R . Prevention of influenza-induced lung injury in mice overexpressing extracellular superoxide dismutase. Am J Physiol Lung Cell Mol Physiol. 2001; 280(1):L69-78. DOI: 10.1152/ajplung.2001.280.1.L69. View

2.
Catania J, Que L, Govert J, Hollingsworth J, Wolfe C . High intensive care unit admission rate for 2013-2014 influenza is associated with a low rate of vaccination. Am J Respir Crit Care Med. 2014; 189(4):485-7. PMC: 3977724. DOI: 10.1164/rccm.201401-0066LE. View

3.
Lee G, Yu J, Cho S, Byun S, Kim D, Lee T . A nucleic-acid hydrolyzing single chain antibody confers resistance to DNA virus infection in hela cells and C57BL/6 mice. PLoS Pathog. 2014; 10(6):e1004208. PMC: 4072776. DOI: 10.1371/journal.ppat.1004208. View

4.
Kwon M, Lee M, Kim K, Park S, Shin H, Jang Y . Production and characterization of an anti-idiotypic single chain Fv that recognizes an anti-DNA antibody. Immunol Invest. 2002; 31(3-4):205-18. DOI: 10.1081/imm-120016241. View

5.
Boltz D, Aldridge Jr J, Webster R, Govorkova E . Drugs in development for influenza. Drugs. 2010; 70(11):1349-62. PMC: 5558450. DOI: 10.2165/11537960-000000000-00000. View